Trillium Therapeutics Inc (TRIL) Stock
TRIL is no longer traded. Trillium Therapeutics was acquired by Pfizer (PFE) on November 17, 2021.
Each TRIL share was exchanged for $18.50 in cash. Prices on this page are historical; the last trade was November 16, 2021 at $18.44.
See Pfizer (PFE) stock →Trillium Therapeutics stock price history
TRIL final trading statistics
- Final close
- $18.44
- Final trading day
- Nov 16, 2021
- Market cap at delisting
- $1.94B
- Shares outstanding
- 105.00M
- Final 52-week range
- $5.80 – $20.96
- Avg. volume (final 3 mo.)
- 3,374,676
- All-time high (split-adj.)
- $222.00 · Mar 2007
- All-time low (split-adj.)
- $0.25 · Aug 2019
- Return since IPO
- -78.3%
- Beta
- 1.90
- Book value / share
- $2.17
- Price / book
- 8.51
Trillium Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2020 | $148.0K | -$59.3M | -$0.71 |
| FY2019 | $124.0K | -$41.6M | -$1.34 |
| FY2018 | $0.00 | -$31.2M | -$2.33 |
| FY2017 | $0.00 | -$35.9M | -$3.54 |
| FY2016 | $0.00 | -$31.7M | -$3.06 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Trillium Therapeutics Inc
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.
Trillium Therapeutics stock FAQ
What happened to Trillium Therapeutics stock?
Trillium Therapeutics was acquired by Pfizer (PFE) on November 17, 2021. Shareholders received $18.50 in cash for each share. TRIL stock stopped trading on the Nasdaq, with a final close of $18.44 on November 16, 2021.
What did Trillium Therapeutics shareholders receive?
Each TRIL share was converted into $18.50 in cash. The deal was valued at about $2.22 billion.
Is TRIL stock still trading?
No. TRIL was delisted from the Nasdaq on November 17, 2021 and no longer trades on a U.S. exchange.
What was the last price of TRIL stock?
TRIL closed at $18.44 on its final trading day, November 16, 2021, for a market value of about $1.94B.
What were Trillium Therapeutics's revenue and earnings in its last full fiscal year?
Trillium Therapeutics reported revenue of $148.0K and net income of -$59.3M in fiscal 2020, its last full year as a public company.
When did Trillium Therapeutics go public?
Trillium Therapeutics Inc stock began trading on March 23, 2005.